Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-KRd vs KRd in Newly Diagnosed Multiple Myeloma
NCT03948035Phase 3Active, not recruiting
- Start
- Aug 2018
- Primary completion
- Aug 2029
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of elotuzumab in multiple myeloma (MM). Started Aug 2018; status: active, not recruiting.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03948035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03948035.